Eli Lilly’s new Lilly Employer Connect platform offers employers more flexible access to obesity drugs like Zepbound, but experts say it represents only incremental progress. The post Lilly Employer Connect Adds Flexibility for Employers But Isn’t Revolutionary, Expert Says appeared first on MedCity News.
AI is racing into everyday medicine. The rules of the road are still being written. Dr. Michelle Mello of Stanford, professor at both the Law School and the School of Medicine, and co-leader of its Healthcare Ethical Assessment Lab for AI, joins Chip to address the questions that trail every advance this series has covered:…
Angel Foster had a backup plan. It was the first weekend in May. A federal appeals court had just made it illegal to mail mifepristone, a pill that’s part of the most widely used abortion method in the U.S. But Foster, a doctor who specializes in reproductive health, was prepared. As leader of the Massachusetts…
Rural hospitals are facing growing cybersecurity threats and digital demands but often lack the resources to respond — a gap Microsoft is working to close through discounted tools, free training and an AI innovation lab. The tech giant’s rural health initiative has reached more than 700 hospitals so far. The post How Microsoft Is Sparking…
While many AI conversations revolve around regulated industry transformation, the question is where to actually start in a way that does not break trust, budgets or regulatory limits. The post The AI Value Gap and Why Validation is a Practical First Win for Life Sciences appeared first on MedCity News.
AllRock Bio’s drug is a small molecule pan-ROCK inhibitor ready for Phase 2 testing in pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The startup is led by the management team that steered CinCor Pharma to a $1.3 billion acquisition by AstraZeneca. The post With Drug Picked Up From Sanofi, Startup AllRock Takes…
Agency looking to deploy artificial intelligence across both digital and voice channels
A new report from the Private Equity Stakeholder Project reveals that private equity firms have been increasingly acquiring intellectual and developmental disability providers and implementing cost-cutting strategies that reduce care quality. The post What’s Private Equity’s Impact on Intellectual and Developmental Disability Services? appeared first on MedCity News.
Significant shares of adults with multiple or complex health conditions, including cancer, lung disease, diabetes, cardiovascular disease, and mental health conditions say they struggle to pay their medical bills and access needed care and medication. These challenges fall hardest on uninsured adults who face greater costs and access challenges.
This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare & Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demonstration programs including the BALANCE Model, and potential impacts on beneficiaries and program budgets.